Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.
PHASE2
The study is being conducted to explore the reasonable dosage and evaluate ...
Status
Not Yet Recruiting
Location
Harbin Medical University Affiliated Cancer Hospital